Skip to main content
Presentation
SAT0463 SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 3 YEARS: LONG-TERM DATA FROM THE FUTURE 1 AND FUTURE 2 STUDIES. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, June 2017
The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology (2017)
  • L Gossec
  • TK Kvien
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Disciplines
Publication Date
June, 2017
Citation Information
L Gossec, TK Kvien, Philip Mease and et.al.. "SAT0463 SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 3 YEARS: LONG-TERM DATA FROM THE FUTURE 1 AND FUTURE 2 STUDIES. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, June 2017" The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology (2017)
Available at: http://works.bepress.com/philip-mease/247/